3B Blackbio DX Ltd

3B Blackbio DX Ltd

₹ 810 -0.95%
24 May - close price
About

Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]

Key Points

Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit

  • Market Cap 608 Cr.
  • Current Price 810
  • High / Low 924 / 390
  • Stock P/E 21.9
  • Book Value 278
  • Dividend Yield 0.31 %
  • ROCE 19.1 %
  • ROE 16.0 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 49.9% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 44.5%
  • Promoter holding has increased by 2.86% over last quarter.

Cons

  • Company has high debtors of 200 days.
  • Working capital days have increased from 161 days to 248 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Healthcare

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
42.69 18.88 32.67 15.22 14.36 18.40 11.69 17.31 14.73 18.11 14.28 19.18 17.67
17.72 10.37 14.46 9.22 7.39 12.48 6.51 8.13 7.42 10.65 7.84 11.39 8.80
Operating Profit 24.97 8.51 18.21 6.00 6.97 5.92 5.18 9.18 7.31 7.46 6.44 7.79 8.87
OPM % 58.49% 45.07% 55.74% 39.42% 48.54% 32.17% 44.31% 53.03% 49.63% 41.19% 45.10% 40.62% 50.20%
1.58 1.19 1.55 1.94 1.54 1.87 1.24 1.96 2.88 1.15 2.96 2.75 2.63
Interest 0.03 0.04 0.03 0.06 0.03 -0.02 0.03 0.07 0.05 0.04 0.02 0.04 0.03
Depreciation 0.23 0.11 0.15 0.18 0.17 0.17 0.17 0.24 0.25 0.21 0.19 0.24 0.32
Profit before tax 26.29 9.55 19.58 7.70 8.31 7.64 6.22 10.83 9.89 8.36 9.19 10.26 11.15
Tax % 25.14% 25.55% 23.70% 23.64% 21.06% 36.91% 24.12% 23.27% 22.04% 37.80% 21.55% 26.02% 23.68%
19.67 7.10 14.94 5.88 6.56 4.82 4.72 8.31 7.72 5.20 7.21 7.58 8.51
EPS in Rs 22.98 8.24 17.53 6.85 7.66 5.53 5.39 11.20 8.96 6.01 9.71 10.46 11.61
Raw PDF
Upcoming result date: 29 May 2024

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
21 20 22 19 17 16 23 23 29 227 81 62 69
20 19 21 18 16 14 18 16 20 77 44 33 39
Operating Profit 1 1 1 1 2 3 5 7 9 150 37 29 31
OPM % 5% 6% 6% 7% 9% 16% 23% 31% 32% 66% 46% 47% 44%
0 0 0 0 0 0 0 1 2 3 7 7 9
Interest 1 1 1 1 1 1 1 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 1 1 1 1 1 1
Profit before tax 0 1 0 0 0 1 5 7 10 152 43 35 39
Tax % 104% 34% 14% 23% 23% 19% 24% 25% 23% 25% 26% 27%
-0 0 0 0 0 1 3 5 8 114 32 26 28
EPS in Rs -0.02 0.62 0.59 0.36 0.51 1.76 5.35 8.18 10.24 151.66 42.89 34.55 37.79
Dividend Payout % 0% 0% 0% 0% 0% 17% 9% 6% 7% 6% 24% 7%
Compounded Sales Growth
10 Years: 12%
5 Years: 22%
3 Years: 29%
TTM: 11%
Compounded Profit Growth
10 Years: 52%
5 Years: 50%
3 Years: 50%
TTM: 20%
Stock Price CAGR
10 Years: 59%
5 Years: 53%
3 Years: 25%
1 Year: 87%
Return on Equity
10 Years: 39%
5 Years: 43%
3 Years: 44%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 6 6 6 6 6 6 6 6 7 7 7 7 9
Reserves 3 3 4 4 4 5 12 16 25 125 146 164 200
6 6 7 8 8 9 6 6 4 2 3 2 1
7 7 7 7 6 6 6 8 9 59 37 41 15
Total Liabilities 22 23 24 25 24 26 30 36 45 194 192 214 225
4 4 4 4 3 3 4 4 4 5 7 8 8
CWIP 0 0 0 0 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 1 59 93 92 96
18 19 20 21 21 22 26 32 40 130 93 114 122
Total Assets 22 23 24 25 24 26 30 36 45 194 192 214 225

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
0 -1 0 0 1 1 2 4 7 98 37 23
-1 0 -0 -0 -0 -0 -1 -1 -1 -70 -28 12
1 -0 0 -0 -1 -0 0 -1 1 -2 -15 -5
Net Cash Flow 1 -1 0 -0 0 0 1 2 7 26 -6 30

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 180 220 213 262 283 321 259 290 252 56 136 200
Inventory Days 109 149 120 145 143 175
Days Payable 165 220 189 218 203 186
Cash Conversion Cycle 124 149 144 188 223 310 259 290 252 56 136 200
Working Capital Days 167 214 218 274 312 377 308 351 302 67 169 248
ROCE % 7% 8% 7% 7% 7% 13% 24% 28% 31% 162% 27% 19%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
38.35% 38.35% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 41.29%
1.47% 0.54% 1.23% 1.64% 1.64% 1.64% 2.11% 2.54% 3.06% 3.16% 3.38% 2.97%
0.09% 0.08% 0.08% 0.08% 0.08% 0.00% 0.00% 0.00% 0.00% 0.82% 1.18% 1.89%
60.09% 61.03% 60.26% 59.85% 59.85% 59.94% 59.47% 59.02% 58.50% 57.60% 56.99% 53.85%
No. of Shareholders 10,54116,25116,75616,46816,31615,41513,79813,13612,41610,51310,0889,753

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls